Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01671514 · ClinicalTrials.gov registry record · NA
Effects of Dark Chocolate on Exercise Capacity, and Mitochondrial Structure and Function
A NA study of Heart Failure and Type 2 Diabetes, sponsored by University of California, San Diego.
- Completed
- Registry status
- NA
- Development phase
- 21
- Enrollment target
- 1
- Study location
NCT01671514: Completed NA study of Heart Failure and Type 2 Diabetes, sponsored by University of California, San Diego.
NCT01671514 is a NA study of Heart Failure and Type 2 Diabetes that has completed, run by University of California, San Diego. The registered enrollment target is 21 participants, below the 2,049-participant average among 397 other Heart Failure trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01671514, a NA study of Heart Failure and Type 2 Diabetes, has completed, sponsored by University of California, San Diego.
- COMPLETED
- Registry status
- NA
- Development phase
- 21 participants
- Enrollment target
- 1
- Study location
Study Summary
The major goal of this study is to characterize the ability of dark chocolate enriched in epicatechin (a component of dark chocolate) to improve the structural and functional features of mitochondria in two groups 1. Patients with heart failure (HF) and type 2 diabetes (DM2) and 2. Normal yet sedentary individuals with impaired baseline exercise capacity (as assessed by VO2 max) We propose that a 3 month treatment with dark chocolate will lead to a significant improvement in exercise capacity which will be secondary to the improvement in skeletal muscle structure from epicatechin.
Primary Outcome
Objectively evaluate exercise capacity through cycle ergometry to measure VO2 max.
Conditions Studied
Interventions
- DIETARY_SUPPLEMENT Epicatechin-enriched dark chocolate
- OTHER Low-epicatechin dark chocolate
Study Locations (1)
California
- University of California, San Diego - La Jolla
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2012-07 |
| Est. Completion | 2014-12 |
| Phase | NA |
What the finished NCT01671514 record still lists
NCT01671514 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 21 participants, a relatively small participant target, below the 2,049-participant average among 397 other Heart Failure trials with a reported enrollment target (99% lower).
The record links to 2 conditions, with Heart Failure appearing as the primary indexed condition, and to 2 interventions - of which Epicatechin-enriched dark chocolate is the first listed.
NCT01671514 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT01671514 about?
NCT01671514 is a clinical study titled "Effects of Dark Chocolate on Exercise Capacity, and Mitochondrial Structure and Function". The major goal of this study is to characterize the ability of dark chocolate enriched in epicatechin (a component of dark chocolate) to improve the structural and functional features of mitochondria in two groups 1. Patients with heart failure (HF) and type 2 diabetes (DM2) and 2. Normal yet seden...
What is the current status of trial NCT01671514?
This trial is currently completed. It is a NA study. The enrollment target is 21 participants. The study started on 2012-07. Estimated completion is 2014-12.
What conditions does trial NCT01671514 study?
This clinical trial studies the following conditions: Heart Failure, Type 2 Diabetes.
What interventions are being tested in trial NCT01671514?
The interventions under investigation include: Epicatechin-enriched dark chocolate (DIETARY_SUPPLEMENT), Low-epicatechin dark chocolate (OTHER).
Who is sponsoring clinical trial NCT01671514?
This trial is sponsored by University of California, San Diego, which has 775 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01671514 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Heart Failure
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01671514's enrollment target sits among peer trials
21 344th of 397 higher than 49 of 397 other Heart Failure trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Heart Failure trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Early Feasibility Study of the NORM™ System in Heart Failure Patients (FUTURE-HFII)
RECRUITING · NA
-
Diuretics Alone vs. Aortix Endovascular Device for Acute Heart Failure
RECRUITING · NA
-
iCardia4HF: Multi-component mHealth Intervention for Patients With Heart Failure
RECRUITING · NA
-
Optimizing Heart Failure Therapies Among Patients With Limited Access in Denver
RECRUITING · NA
-
Hemodynamic Monitoring to Prevent Adverse Events foLlowing cardiOgenic Shock Trial
RECRUITING · NA
-
Effect of a Quality Improvement Initiative to Address Social Determinants of Health on Rehospitalization Rates in Patients With Heart Failure
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02447874 · 21 participants · Phase 1
Arginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease
- NCT03826992 · 21 participants · Phase 1
Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia
- NCT04107077 · 21 participants · Phase 2
Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer
- NCT04158635 · 21 participants · Phase 1
Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia